LecturaInvestigaciónRadarMarco de inversión
Iniciar sesión / Registrarse
← Volver a la lectura
NoticiasMaterial2 min de lecturaEditorial de DisconfirmAI

OpenAI releases MedChemBench: GPT-6.2 Astra scores 84.5% on medicinal chemistry reasoning

OpenAI's new benchmark tests AI on molecular structure and drug property prediction, showing strong structural reconstruction but weaker compound selection.

2026-11-20 08:00 GMT+8

OpenAI has introduced MedChemBench, a benchmark designed to evaluate how well large language models can perform reasoning tasks in medicinal chemistry. The benchmark consists of 99 problems drawn from 117 published papers and patents, covering 761 distinct molecular structures. It tests four specific capabilities: reconstructing correct molecular structures from drawings, explaining experimental evidence, ranking and selecting compounds based on stated requirements, and predicting numerical properties such as solubility or metabolic stability.

At the highest reasoning setting (xhigh), OpenAI's latest model, GPT-6.2 Astra, achieved 84.5% of the available credit. This compares to 83.3% for GPT-6 Astra, 82.0% for GPT-6.1 Sol, and 58.2% for GPT-5.6 Sol. The results highlight a significant gap between different abilities: Astra performed exceptionally well at reconstructing molecular structures, earning 95.4% of the available credit in that component, but struggled with selecting compounds and predicting their numerical properties, where it earned only about half the available credit.

One illustrative problem involves inhibitors of PRMT5, a protein target in cancer research. Models were given earlier experimental data and asked to predict how three related compounds would behave regarding cellular potency, cell permeability, and liver enzyme breakdown. Later experiments, which were withheld from the model, revealed tradeoffs: one compound had higher potency but lower permeability, while another broke down more slowly. This reflects the central challenge in medicinal chemistry, where improving one property often degrades another.

OpenAI notes important limitations. These results do not establish whether models can discover new drugs or improve real-world laboratory decisions. Prior exposure to the published sources cannot be ruled out, and each response was a single attempt without tools, feedback, or new experiments. The benchmark evaluates reasoning from historical evidence rather than live drug discovery workflows.

Iniciar sesión / Registrarse
LecturaInvestigaciónRadarMarco de inversión

Fuentes

  • openai.comOpenAI↗
Continuar investigando →